Vitex
This article was originally published in The Gray Sheet
Executive Summary
Next-generation Universal PLAS+ SD plasma transfusion product commences Phase III pivotal trials, which should conclude in the second half of 2000. A biologics license application submission is expected this year. The product is designed to inactivate lipid-enveloped viruses including HIV, hepatitis C and B without being specific to any blood type